Using medical honey to treat wounds in intensive care patients
Medical Honey for Wound Treatment in Intensive Care. (MICARéa) Randomized, Controlled, Single-center Pilot Study.
This study is trying to see if using medical honey can help heal wounds better than regular care for patients in intensive care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Angers Government |
| Locations | 1 site (Angers) |
| Trial ID | NCT06150326 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of medical honey (Activon®) in treating acute cutaneous wounds in patients within an intensive care unit, compared to standard wound care practices. It is a randomized, single-blind, controlled trial where patients with one or more acute wounds will be assigned to receive either honey treatment or standard care. The primary outcome will be the percentage reduction in wound surface area after 15 days of treatment. The study seeks to address the gap in knowledge regarding the use of honey for wound management in critically ill patients.
Who should consider this trial
Good fit: Ideal candidates are critically ill patients with one or more acute wounds that are less than 8 days old.
Not a fit: Patients with chronic wounds, those with known allergies to honey, or those with a life expectancy of less than 15 days may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a simpler and more effective treatment option for wound healing in critically ill patients.
How similar studies have performed: Previous studies have shown that honey can be effective in treating chronic and acute wounds, but this specific application in intensive care patients is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalization in surgical intensive care unit A -USC PTO CHU ANGERS * Informed consent signed by patient or relative (or emergency inclusion procedure) * Patient with one or more wounds ≥ 4 cm2, evolving for less than 8 days, including: stage 2, 3, 4 pressure sores, lacerations, ulcers, dermabrasions and scar disunions. Exclusion Criteria: * Patients with honey intolerance/allergy to bee stings * Patients with wounds lasting more than 8 days * Patient with a bleeding wound, * Patient with a tunneled wound * Patients with chronic dermatoses * Patient with an estimated life expectancy \< 15 days * Expected discharge ≤48 hours. * No affiliation to a French social security scheme or beneficiary of such a scheme. * Pregnant, breast-feeding or parturient woman * Person deprived of liberty by judicial or administrative decision * Person subject to a legal protection measure
Where this trial is running
Angers
- Angers University Hospital, surgical reanimation — Angers, France (Recruiting)
Study contacts
- Principal investigator: catherine ROD — anethesia and critical care department, CHU Angers
- Study coordinator: Catherine CR ROD, NURSE
- Email: arcdar-angers@chu-angers.fr
- Phone: 0241353635
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.